Gregory Alan Korbel Aprea Therapeutics, Inc. (APRE) insider trading activity

Gregory Alan Korbel is SVP, Chief Operating Officer of Aprea Therapeutics, Inc.. Currently has a direct ownership of 45,762 shares of APRE, which is worth approximately $174,810. The most recent transaction as insider was on Jul 28, 2022, when has been sold 24,300 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 45.8K

0% 3M change

0% 12M change

Total Value Held $174,810

Gregory Alan Korbel Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 28 2022	BUY Grant, award, or other acquisition	-	24,300 Added 34.68%	45,762 Common Stock
Jun 03 2022	SELL Payment of exercise price or tax liability	$6,712 $0.8 p/Share	8,390 Reduced 28.11%	21,462 Common Stock
Mar 10 2022	SELL Payment of exercise price or tax liability	$3,620 $1.82 p/Share	1,989 Reduced 6.25%	29,852 Common Stock
Mar 10 2022	BUY Grant, award, or other acquisition	-	16,000 Added 33.44%	31,841 Common Stock
Feb 25 2022	SELL Payment of exercise price or tax liability	$2,307 $1.74 p/Share	1,326 Reduced 7.72%	15,841 Common Stock
Dec 01 2021	SELL Open market or private sale	$108,900 $3.96 p/Share	27,500 Reduced 61.57%	17,167 Common Stock
Dec 01 2021	BUY Exercise of conversion of derivative security	$25,300 $0.92 p/Share	27,500 Added 38.11%	44,667 Common Stock

Nov 01 2021	SELL Open market or private sale	$137,500 $5.0 p/Share	27,500 Reduced 61.57%	17,167 Common Stock
Nov 01 2021	BUY Exercise of conversion of derivative security	$25,300 $0.92 p/Share	27,500 Added 38.11%	44,667 Common Stock
Oct 01 2021	SELL Open market or private sale	$134,475 $4.89 p/Share	27,500 Reduced 61.57%	17,167 Common Stock
Oct 01 2021	BUY Exercise of conversion of derivative security	$25,300 $0.92 p/Share	27,500 Added 38.11%	44,667 Common Stock
Sep 20 2021	SELL Open market or private sale	$164,141 $4.98 p/Share	32,960 Reduced 65.75%	17,167 Common Stock
Sep 20 2021	BUY Exercise of conversion of derivative security	$25,300 $0.92 p/Share	27,500 Added 38.11%	44,667 Common Stock
Sep 10 2021	SELL Payment of exercise price or tax liability	$7,913 $4.59 p/Share	1,724 Reduced 7.08%	22,627 Common Stock
Aug 25 2021	SELL Payment of exercise price or tax liability	$4,573 $3.98 p/Share	1,149 Reduced 4.51%	24,351 Common Stock
Mar 10 2021	BUY Grant, award, or other acquisition	-	15,000 Added 37.04%	25,500 Common Stock
Feb 25 2021	BUY Grant, award, or other acquisition	-	10,000 Added 48.78%	10,500 Common Stock

GAK

Gregory Alan Korbel

SVP, Chief Operating Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APRE shares.

Notify only if

Value

Insider Trading

Get notified when an Aprea Therapeutics, Inc. insider buys or sells APRE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aprea Therapeutics, Inc.

Track Activities on APRE

Account